Challenger Tells Federal Circuit Patent Wrongly Deemed Nonobvious
Mealey's (September 29, 2017, 11:40 AM EDT) -- WASHINGTON, D.C. — A decision by the Patent Trial and Appeal Board that confirmed the patentability of the rheumatoid arthritis drug Orencia despite findings in the same ruling that a person...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login